Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Tarsus Pharmaceuticals Inc (TARS)

251 + Investors. Track Smart Money conviction in TARS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +7
Streak
7Q ▲
Buyers last Q
53%

Smart Money Signals — TARS

Based on 252 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added TARS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
252 hedge funds hold TARS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +33% more funds vs a year ago

fund count last 6Q
+62 new funds entered over the past year (+33% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 53% buying

137 buying123 selling
Last quarter: 137 funds bought or added vs 123 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-8 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 43 → 36 → 54 → 46. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 37% long-term, 31% new

■ 37% conviction (2yr+) ■ 33% medium ■ 31% new
Of the 252 current holders: 92 (37%) held >2 years, 82 held 1–2 years, and 78 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares +2%, value -15%

Value
-14%
Shares
+1%
Last quarter: funds added +2% more shares while total portfolio value only changed -15%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

38 → 43 → 36 → 54 → 46 new funds/Q
New funds entering each quarter: 43 → 36 → 54 → 46. A growing number of institutions are discovering TARS each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 40% veterans vs 36% newcomers

■ 40% veterans ■ 24% 1-2yr ■ 36% new
Entry-cohort mix of 258 holders: 103 (40%) are 2+ year veterans, 63 entered 1–2 years ago, and 92 (36%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds
49 of 251 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.2
out of 10
Moderate Exit Risk
Exit risk score 4.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TARS

In 2026 Q1, 137 hedge funds were net buyers of TARS (46 opened a new position, 91 added to an existing one), while 123 reduced or exited (84 trimmed, 39 sold completely) — a 53% buyer ratio, indicating a slight buying edge. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 36% of total institutional value in TARS is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +7 funds (more new holders than closures). Total institutional holders: 252.

Hedge Fund Ownership: TARS

How many hedge funds hold TARS — quarterly history vs. share price
Quarterly hedge fund ownership of TARS vs. share price

Market Analysis: TARS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TARS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Tarsus Pharmaceuticals Inc (TARS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TARS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
TARS
-11.7%
XLV
+4.9%

TARS outperformed XLV by -16.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
TARS
-0.8%
XLV
+6.0%

Since the filing became public, TARS outperformed XLV by -6.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

30 top-rated funds 2 high-conviction
Consensus
6.5
/ 10
breadth
×
Elite
3.3
/ 10
conviction
Hedge Fund Positioning: TARS
251 + Investors

Track Smart Money conviction in TARS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 251 245 2.45%
13F Shares 46M 45M 1.71%
Total Value $3.09B $3.61B -14.54%
New Positions 45 54 -9
Increased Positions 90 87 +3
Closed Positions 39 26 +13
Reduced Positions 82 81 +1
Total Calls 4 4 -
Total Puts 3 1 200.0%
PUT/CALL Ratio 0.75 0.25 Neutral

Statistics: TARS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

251 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TARS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 TARS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Ally Bridge Group (NY) LLC 4.58% 80,859 $5.7M
2 Tang Capital Management LLC 4.23% 1,188,624 $83.4M
3 Deep Track Capital, LP 4.12% 3,600,000 $252.5M
4 Paradigm Biocapital Advisors LP 3.67% 2,562,154 $179.7M
5 Tri Locum Partners LP 2.49% 252,588 $17.7M
6 Rtw Investments, LP 2.34% 3,346,025 $234.7M
7 GordonMD Global Investments LP 2.09% 42,680 $3.0M
8 MPM BioImpact LLC 1.79% 329,750 $23.1M
9 Sands Capital Alternatives, LLC 1.42% 85,000 $6.0M
10 Frazier Life Sciences Management, L.P. 1.32% 728,644 $51.1M
11 HighVista Strategies LLC 1.02% 52,464 $3.7M
12 Rock Springs Capital Management LP 0.93% 225,179 $15.8M
13 Cormorant Asset Management, LP 0.79% 225,000 $15.8M
14 Lisanti Capital Growth, LLC 0.74% 41,815 $2.9M
15 Sectoral Asset Management Inc 0.71% 11,272 $852K
16 Integral Health Asset Management, LLC 0.67% 200,000 $14.0M
17 Braidwell LP 0.62% 265,715 $18.6M
18 PFM Health Sciences, LP 0.51% 80,226 $5.6M
19 Verdad Advisers, LP 0.50% 6,328 $444K
20 Driehaus Capital Management LLC 0.48% 926,125 $65.0M
21 Seven Fleet Capital Management LP 0.44% 19,800 $1.4M
22 Vestal Point Capital, LP 0.39% 200,000 $14.0M
23 VARCOV Co. 0.39% 14,875 $1.0M
24 Odyssean, LLC 0.35% 13,737 $964K
25 PSP Research LLC 0.35% 7,000 $491K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Tarsus Pharmaceuticals Inc (TARS)

What does the Smart Money Trend signal show for TARS?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added TARS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TARS?

Slight buying edge — 53% buying: Last quarter: 137 funds bought or added vs 123 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for TARS holders?

Strong quality — 36% AUM from major funds: 49 of 251 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TARS?

Mixed — 37% long-term, 31% new: Of the 252 current holders: 92 (37%) held >2 years, 82 held 1–2 years, and 78 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Tarsus Pharmaceuticals Inc (TARS) following the 2026 Q1 hedge fund 13F filings?

As of today, TARS has moved -0.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -6.8%. Since the quarter end (March 31, 2026), TARS has gained -11.7% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →